Fucidin® Cream in the Treatment of Impetigo
Launched by LEO PHARMA · Sep 29, 2009
Trial Information
Current as of May 19, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with a clinical diagnosis of impetigo,
- • Patients aged 2-11 years,
- • Patients of either sex,
- • Patients whose parent(s) has(ve) provided written consent, AND
- • Patients with a severity score of 1 for at least one of the following signs: pustules/infected bullae, erythema and infiltration/induration.
- Exclusion Criteria:
- • Patients with other active inflammatory dermatitis at the area of impetigo,
- • Patients with a temperature above 38.5 C rectally (or equivalent), OR
- • Patients who have been administered topical or systemic Fucidin® or other antibacterial agents within the previous 4 weeks.
About Leo Pharma
LEO Pharma is a global pharmaceutical company dedicated to developing innovative therapies for dermatological and critical care conditions. With a strong focus on research and development, LEO Pharma aims to improve the lives of patients through advanced treatments and a commitment to high-quality standards. The company collaborates with healthcare professionals and stakeholders to address unmet medical needs and drive scientific progress in the field. Through its clinical trials, LEO Pharma seeks to enhance therapeutic options and provide effective solutions for patients suffering from skin diseases and other related health issues.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bergen, , Norway
Göteborg, , Sweden
Patients applied
Trial Officials
Medical Expert
Study Director
LEO Pharma
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials